Nanobiotix announces the launch of curadigm : a new nanotechnology platform for healthcare
28 5월 2019 - 2:00PM
NANOBIOTIX ANNOUNCES THE LAUNCH
OF CURADIGM: A NEW NANOTECHNOLOGY PLATFORM FOR
HEALTHCARE
- Curadigm opens new growth pathways for Nanobiotix
beyond oncology, built on the success and know-how established
through the development of NBTXR3
- Curadigm will operate as a
wholly-owned subsidiary of Nanobiotix and the platform will
be further developed through multiple anticipated
partnerships
- Curadigm “Nanoprimer” technology aims to prime the body
to receive various therapeutics and could reshape the balance
between efficacy and toxicity for patients
- In vivo proof of concept data were
presented during AACR 2019
“After
achieving the milestone of our first European market approval for
Nanobiotix’s lead oncology product candidate, NBTXR3, our business
continues to build momentum. We are thrilled to announce the launch
of our subsidiary, Curadigm—another disruptive technology platform
we have built as a result of pioneering nanomedicine for more than
15 years. While Nanobiotix remains focused on continued development
of NBTXR3, we are pleased to open new growth pathways for our
business and shareholders.” – Laurent Levy, CEO of Nanobiotix
Paris, France and Cambridge,
Massachusetts, USA, May 28, 2019 –
NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage
nanomedicine company pioneering new approaches to the treatment of
cancer, today announced the launch of new subsidiary Curadigm,
dedicated to redefining the therapeutic balance between
bioavailability, toxicity, and efficacy across the pharmaceutical
industry. The company will be a wholly-owned subsidiary of
Nanobiotix and operate in France and in the US with a
dedicated team committed to growth and potential financing
opportunities.
For most therapeutics today, only a small
portion of the medicine administered is effective and the rest is
cleared from the body without effect or may even be toxic. After
injection, the dose moves through the circulatory system within the
blood, and while a small portion reaches the targeted tissue the
remainder is cleared or accumulates in organs such as the
liver.
Curadigm technology aims to change this balance
through proprietary “Nanoprimer” technology. Leveraging over 15
years of experience in the development of nanotechnology at
Nanobiotix, the company has created nano-scale objects that prime
the body for treatment. These nanoparticles, called nanoprimers,
have been designed with specific physico-chemical properties that
allow them to transiently occupy the liver cells responsible for
therapeutic clearance. Injected prior to the therapeutic, the
nanoprimer increases systemic bioavailability allowing for
increased accrual in the target tissue and therapeutic action.
Curadigm technology shows potential to have
broad implications across the healthcare system through its
opportunity to increase the efficacy of therapeutics at their
current dose, lower the necessary dose thereby decreasing toxicity
and cost, and allow for novel therapeutic approaches (e.g. new
approaches to drug design). In Vivo data proving the concept was
published by Nanobiotix in Scientific Reports1 and presented at
AACR2019.2
Curadigm will be led by Dr. Matthieu Germain,
who holds deep expertise in the development of nanoparticles after
more than 15 years with Nanobiotix, including initial development
of the new technology. Dr. Kate Rochlin, leveraging her strong
background in early stage company growth, will join the company as
Director of Business Development. Under their leadership, Curadigm
will maintain the same core values and spirit of its parent
company—to significantly improve outcomes for millions of patients
through a disruptive approach for therapeutics across
healthcare.
- M. Germain et al., Priming the body to receive the therapeutic
agent to redefine treatment benefit/risk profile, SCIENTIFIC
REPORTS (2018) 8:4797
- L. Poul et al., Prime the body to receive the treatment: how to
improve nanomedicines efficacy, AACR 2019, poster 3613
-Ends-
About NANOBIOTIX:
www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a leading,
clinical-stage nanomedicine company pioneering new approaches to
significantly change patient outcomes by bringing nanophysics to
the heart of the cell.
The Nanobiotix philosophy is rooted in designing
pioneering, physical-based approaches to bring highly effective and
generalized solutions to address unmet medical needs and
challenges.
Nanobiotix’s first-in-class, proprietary lead
technology, NBTXR3, aims to expand radiotherapy benefits for
millions of cancer patients. Nanobiotix’s Immuno-Oncology program
has the potential to bring a new dimension to cancer
immunotherapies.
Nanobiotix is listed on the regulated market of
Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg:
NANO: FP). The Company’s headquarters are in Paris, France, with a
U.S. affiliate in Cambridge, MA, and European affiliates in Spain
and Germany.
About
CURADIGM: www.curadigm.com
Curadigm, a wholly-owned subsidiary of
Nanobiotix S.A., will be incorporated this year in France and will
aim to expand treatment benefits by increasing drug bioavailability
while decreasing unintended off-target effects, specifically liver
and spleen toxicities.
The Curadigm platform is being developed for use
across multiple therapeutic classes to utilize biocompatible
nanoparticles to transiently occupy the pathway responsible for
therapeutic clearance and hepatic toxicity.
The Curadigm platform is dedicated to bringing
broadly applicable delivery technologies to patients to increase
efficacy in both current & novel therapeutics and improve
patient outcomes.
Contact
Nanobiotix |
Communications Department+33 (0)1 40 26 07
55+1 (617) 852-4835contact@nanobiotix.com |
Investor Relations
Department+33 (0)1 79 97 29 99+1 (646)
241-4400investors@nanobiotix.com |
Media relations |
France - Springbok
ConsultantsMarina Rosoff+33 (0)6 71 58 00
34marina@springbok.fr |
|
United States –
RooneyPartners Marion Janic +1
(212) 223-4017mjanic@rooneyco.com |
|
Disclaimer
This press release contains certain
forward-looking statements concerning Nanobiotix and its business,
including its prospects and product candidate development. Such
forward-looking statements are based on assumptions that Nanobiotix
considers to be reasonable. However, there can be no assurance that
the estimates contained in such forward-looking statements will be
verified, which estimates are subject to numerous risks including
the risks set forth in the reference document of Nanobiotix
registered with the French Financial Markets Authority (Autorité
des Marchés Financiers) under number R.19-018 on April 30, 2019 (a
copy of which is available on www.nanobiotix.com) and to the
development of economic conditions, financial markets and the
markets in which Nanobiotix operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Nanobiotix or not currently considered
material by Nanobiotix. The occurrence of all or part of such risks
could cause actual results, financial conditions, performance or
achievements of Nanobiotix to be materially different from such
forward-looking statements.
- Nanobiotix_PR_launch_Curadigm_VFF
Nanobiotix (EU:NANO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Nanobiotix (EU:NANO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024